Although cetuximab, an anti-EGFR monoclonal antibody, failed to achieve satisfactory outcomes in GC, it was reported that cells with EGFR signaling activation were less responsive to oxaliplatin19, while blocking EGFR enhanced the effect of oxaliplatin on GC cell lines11. Here, EGFR is linked to gastric cancer.